Gilead Sciences Inc (LTS:0QYQ) Stock News, Headlines & Updates
Gilead Sciences Inc Stock News from GuruFocus
- 1
Oct 22, 2024
Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024
Business Wire • 9:00am
Oct 09, 2024
Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024
Business Wire • 4:00pm
Gilead Sciences Inc (GILD) Q2 2024 Earnings Call Highlights: Strong Growth in HIV and Oncology Segments
GuruFocus News • 3:52pm
Q2 2024 Gilead Sciences Inc Earnings Call Transcript
GuruFocus News • 1:44pm
Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
Business Wire • 8:00am
Oct 08, 2024
Gilead Sciences: New Report Shows Every Country in the World Must Do More To End the HIV Epidemic
ACCESSWIRE • 11:00am
Oct 07, 2024
Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
Business Wire • 11:00am
Oct 03, 2024
Insider Sale: Chief Medical Officer Merdad Parsey Sells 2,000 Shares of Gilead Sciences Inc (GILD)
GuruFocus News • 7:04pm
Oct 02, 2024
Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries
PRNewswire • 10:00am
Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries
Business Wire • 8:00am
Sep 25, 2024
Championing HIV Services for LGBTQ+ Youth
ACCESSWIRE • 11:00am
Sep 18, 2024
Working to Build Next-Generation Cancer Therapies
ACCESSWIRE • 3:00pm
Sep 14, 2024
Insider Sale: Johanna Mercier Sells 29,357 Shares of Gilead Sciences Inc (GILD)
GuruFocus Research • 11:51pm
Sep 12, 2024
Helping End HIV - Gilead Sciences
ACCESSWIRE • 11:00am
Gilead's Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial
Business Wire • 8:00am
Sep 10, 2024
Seramount Ranks Gilead Sciences Among Its Leading Inclusion Index Company
ACCESSWIRE • 11:00am
Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies
Business Wire • 8:00am
Sep 06, 2024
Gilead Sciences: Living With a Rare Liver Disease: Maria's Journey
ACCESSWIRE • 11:00am
Sep 05, 2024
Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer
Business Wire • 8:00am
Sep 04, 2024
Gilead Sciences: Innovative Approaches to Healthcare Can Remove Barriers
ACCESSWIRE • 11:00am
Aug 30, 2024
Insider Sale: Johanna Mercier Sells 9,513 Shares of Gilead Sciences Inc (GILD)
GuruFocus Research • 11:46pm
Aug 27, 2024
“The Adventure Jar,” Showcases a Family Navigating the Challenges of a Cancer Diagnosis and Finding Magic in Time Together
ACCESSWIRE • 11:00am
Aug 21, 2024
Gilead Sciences to Present at Upcoming Investor Conferences
Business Wire • 4:00pm
Aug 20, 2024
Gilead Sciences: "One of Best Employers for Women" by Forbes
ACCESSWIRE • 11:00am
Building a Bridge to a Healthier World for Youth in Africa with Gilead Sciences
ACCESSWIRE • 11:00am
Aug 14, 2024
Insider Sale: Johanna Mercier Sells 5,490 Shares of Gilead Sciences Inc (GILD)
GuruFocus Research • 3:01pm
Gilead's Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA
Business Wire • 1:00pm
Aug 13, 2024
Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership To Help Address the Growing HIV Crisis in Eastern Europe and Central Asia
ACCESSWIRE • 11:00am
Aug 09, 2024
Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight
GuruFocus Research • 11:12pm
Aug 08, 2024
Gilead Sciences Announces Second Quarter 2024 Financial Results
Business Wire • 4:00pm
Gilead Sciences (GILD) Q2 2024 Earnings: EPS of $1.29 Beats Estimates, Revenue Hits $7.0 Billion
GuruFocus Research • 3:51pm
Closing the HIV Diagnosis Gap in Germany with Gilead Sciences
ACCESSWIRE • 11:00am
Aug 07, 2024
Gilead Sciences Inc (GILD) Q2 2024: Everything You Need To Know Ahead Of Earnings
GuruFocus Research • 7:01am
- 1
Show
Entries
Headlines
Total 0- 1
No recent news